135 related articles for article (PubMed ID: 38299539)
1. Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500).
Black WC; Abdoli A; An X; Auger A; Beaulieu P; Bernatchez M; Caron C; Chefson A; Crane S; Diallo M; Dorich S; Fader LD; Ferraro GB; Fournier S; Gao Q; Ginzburg Y; Hamel M; Han Y; Jones P; Lanoix S; Lacbay CM; Leclaire ME; Levy M; Mamane Y; Mulani A; Papp R; Pellerin C; Picard A; Skeldon A; Skorey K; Stocco R; St-Onge M; Truchon JF; Truong VL; Zimmermann M; Zinda M; Roulston A
J Med Chem; 2024 Feb; 67(4):2349-2368. PubMed ID: 38299539
[TBL] [Abstract][Full Text] [Related]
2. RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.
Roulston A; Zimmermann M; Papp R; Skeldon A; Pellerin C; Dumas-Bérube É; Dumais V; Dorich S; Fader LD; Fournier S; Li L; Leclaire ME; Yin SY; Chefson A; Alam H; Yang W; Fugère-Desjardins C; Vignini-Hammond S; Skorey K; Mulani A; Rimkunas V; Veloso A; Hamel M; Stocco R; Mamane Y; Li Z; Young JTF; Zinda M; Black WC
Mol Cancer Ther; 2022 Feb; 21(2):245-256. PubMed ID: 34911817
[TBL] [Abstract][Full Text] [Related]
3. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
Yap TA; Fontana E; Lee EK; Spigel DR; Højgaard M; Lheureux S; Mettu NB; Carneiro BA; Carter L; Plummer R; Cote GM; Meric-Bernstam F; O'Connell J; Schonhoft JD; Wainszelbaum M; Fretland AJ; Manley P; Xu Y; Ulanet D; Rimkunas V; Zinda M; Koehler M; Silverman IM; Reis-Filho JS; Rosen E
Nat Med; 2023 Jun; 29(6):1400-1411. PubMed ID: 37277454
[TBL] [Abstract][Full Text] [Related]
4. ATR inhibitor, camonsertib, dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).
Fontana E; Rosen E; Lee EK; Højgaard M; Mettu NB; Lheureux S; Carneiro BA; Cote GM; Carter L; Plummer R; Mahalingam D; Fretland AJ; Schonhoft JD; Silverman IM; Wainszelbaum M; Xu Y; Ulanet D; Koehler M; Yap TA
J Natl Cancer Inst; 2024 May; ():. PubMed ID: 38710487
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase.
Duan Y; Cheng H; Zhuang L; Xia J; Xu Y; Zhang R; Sun R; Lu T; Chen Y
Eur J Med Chem; 2023 Jul; 255():115370. PubMed ID: 37130473
[TBL] [Abstract][Full Text] [Related]
6. Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib.
Rosen E; Yap TA; Lee EK; Højgaard M; Mettu NB; Lheureux S; Carneiro BA; Plummer R; Fretland AJ; Ulanet D; Xu Y; McDougall R; Koehler M; Fontana E
Clin Cancer Res; 2024 Feb; 30(4):687-694. PubMed ID: 38078898
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo.
Bin H; Chen P; Wu M; Wang F; Lin G; Pan S; Liu J; Mu B; Nan J; Huang Q; Li L; Yang S
Eur J Med Chem; 2022 Mar; 232():114187. PubMed ID: 35183872
[TBL] [Abstract][Full Text] [Related]
8. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer.
Shao J; Huang L; Lai W; Zou Y; Zhu Q
Molecules; 2023 Jun; 28(11):. PubMed ID: 37298997
[TBL] [Abstract][Full Text] [Related]
10. ATM and ATR as therapeutic targets in cancer.
Weber AM; Ryan AJ
Pharmacol Ther; 2015 May; 149():124-38. PubMed ID: 25512053
[TBL] [Abstract][Full Text] [Related]
11. Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present.
Hu S; Hui Z; Duan J; Garrido C; Xie T; Ye XY
Expert Opin Ther Pat; 2022 Apr; 32(4):401-421. PubMed ID: 35001778
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 6,7-dihydro-5H-pyrrolo[3,4-d] pyrimidine derivatives as a new class of ATR inhibitors.
Chen P; Bin H; Jiao Y; Lin G; Zhang Y; Xia A; Pan Z; Qiao J; Guo Y; Liu J; Zhou Y; Li L
Bioorg Med Chem Lett; 2022 May; 63():128651. PubMed ID: 35245663
[TBL] [Abstract][Full Text] [Related]
13. Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
Knegtel R; Charrier JD; Durrant S; Davis C; O'Donnell M; Storck P; MacCormick S; Kay D; Pinder J; Virani A; Twin H; Griffiths M; Reaper P; Littlewood P; Young S; Golec J; Pollard J
J Med Chem; 2019 Jun; 62(11):5547-5561. PubMed ID: 31074988
[TBL] [Abstract][Full Text] [Related]
14. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Wengner AM; Siemeister G; Lücking U; Lefranc J; Wortmann L; Lienau P; Bader B; Bömer U; Moosmayer D; Eberspächer U; Golfier S; Schatz CA; Baumgart SJ; Haendler B; Lejeune P; Schlicker A; von Nussbaum F; Brands M; Ziegelbauer K; Mumberg D
Mol Cancer Ther; 2020 Jan; 19(1):26-38. PubMed ID: 31582533
[TBL] [Abstract][Full Text] [Related]
15. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
Lücking U; Wortmann L; Wengner AM; Lefranc J; Lienau P; Briem H; Siemeister G; Bömer U; Denner K; Schäfer M; Koppitz M; Eis K; Bartels F; Bader B; Bone W; Moosmayer D; Holton SJ; Eberspächer U; Grudzinska-Goebel J; Schatz C; Deeg G; Mumberg D; von Nussbaum F
J Med Chem; 2020 Jul; 63(13):7293-7325. PubMed ID: 32502336
[TBL] [Abstract][Full Text] [Related]
16. Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis.
Biswas H; Makinwa Y; Zou Y
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511442
[TBL] [Abstract][Full Text] [Related]
17. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I
Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572
[TBL] [Abstract][Full Text] [Related]
18. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
Szychowski J; Papp R; Dietrich E; Liu B; Vallée F; Leclaire ME; Fourtounis J; Martino G; Perryman AL; Pau V; Yin SY; Mader P; Roulston A; Truchon JF; Marshall CG; Diallo M; Duffy NM; Stocco R; Godbout C; Bonneau-Fortin A; Kryczka R; Bhaskaran V; Mao D; Orlicky S; Beaulieu P; Turcotte P; Kurinov I; Sicheri F; Mamane Y; Gallant M; Black WC
J Med Chem; 2022 Aug; 65(15):10251-10284. PubMed ID: 35880755
[TBL] [Abstract][Full Text] [Related]
19. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Bradbury A; Hall S; Curtin N; Drew Y
Pharmacol Ther; 2020 Mar; 207():107450. PubMed ID: 31836456
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
Foote KM; Nissink JWM; McGuire T; Turner P; Guichard S; Yates JWT; Lau A; Blades K; Heathcote D; Odedra R; Wilkinson G; Wilson Z; Wood CM; Jewsbury PJ
J Med Chem; 2018 Nov; 61(22):9889-9907. PubMed ID: 30346772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]